Status:
COMPLETED
Accelerated Diffusion MRI for Diagnosis of Hungtington Disease
Lead Sponsor:
Wang . Jiun-Jie
Collaborating Sponsors:
National Health Research Institutes, Taiwan
Conditions:
Huntington Disease
Eligibility:
All Genders
20-70 years
Brief Summary
The hypotheses of the project are 1. Diffusion MRI using compressed sensing could have reduced motion sensitivity and improved susceptibility related artifact because of accelerated acquisition. 2. T...
Detailed Description
Diffusion magnetic resonance imaging has emerged as a sensitive, noninvasive tool for assessing the abnormalities in the central nervous system. Applications have been reported in many neurological di...
Eligibility Criteria
Inclusion
- Huntington Disease
- All participants should be aged between 20 and 70 year old.
- Established diagnosis by a neurological examination and genetic assessment of CAG expansion in the Htt gene.
- Able to understand and provide signed informed consent.
- Healthy Controls:
- Able to understand and provide signed informed consent
- age range and gender matched with Patients with HD
- without significant neuropsychiatric disorders
Exclusion
- Human Subjects The participants will be divided into 2 groups: Huntington Disease Group and Healthy Control Group. All participants should be aged between 20 and 70 year old, right handed and gender balanced.
- Exclusion CriteriaThe following exclusion criteria apply to both groups.
- Cardiac pacemaker implantation.
- Implantation of intracranial metal device.
- Significant major systemic disease, such as renal failure, heart failure, stroke, AMI/unstable angina, poor controlled diabetes mellitus, poor controlled hypertension.
- Pregnant or breast feeding women.
- Severe dementia.
- Any documented abnormality of brain caused by etiologies other than HD by MRI and 18FDG PET studies, which might contribute to the cognitive function, such as hydrocephalus or encephalomalacia, will be excluded. Mild cortical atrophy will be allowed.
- History of intracranial operation, including thalamotomy, pallidotomy, and/or deep brain stimulation.
- Significant physical disorder or neuropsychiatric disorder.
Key Trial Info
Start Date :
January 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2017
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT01884181
Start Date
January 1 2014
End Date
December 1 2017
Last Update
July 18 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ChangGung Memorial Hospital, Linkou
Taoyuan District, Taiwan, 333